142 related articles for article (PubMed ID: 35224264)
1. Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors.
Matsumoto T; Shiota M; Yamada S; Blas L; Naganuma H; Lee K; Monji K; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
JMA J; 2022 Jan; 5(1):83-90. PubMed ID: 35224264
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
Clin Genitourin Cancer; 2017 Dec; 15(6):e1073-e1080. PubMed ID: 28826931
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer.
Yamada S; Shiota M; Blas L; Matsumoto T; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
Prostate Int; 2022 Mar; 10(1):50-55. PubMed ID: 35510101
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan.
Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
Clin Genitourin Cancer; 2018 Jun; 16(3):219-225. PubMed ID: 29274813
[TBL] [Abstract][Full Text] [Related]
5. Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients.
Kobayashi H; Shiota M; Sato N; Kobayashi S; Matsumoto T; Monji K; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
Anticancer Drugs; 2022 Jan; 33(1):e541-e547. PubMed ID: 34387597
[TBL] [Abstract][Full Text] [Related]
6. The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study.
Naito Y; Kato M; Kawanishi H; Yuguchi Y; Yuba T; Ishikawa T; Hattori K; Yamamoto A; Sano T; Matsukawa Y; Kimura T; Nishikimi T; Hattori R; Tsuzuki T; Gotoh M
Prostate; 2020 Nov; 80(15):1373-1380. PubMed ID: 32914895
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy.
Min K; Chung JW; Ha YS; Lee JN; Kim BS; Kim HT; Kim TH; Yoo ES; Kwon TG; Chung SK; Tanaka M; Egawa S; Kimura T; Choi SH
World J Mens Health; 2020 Apr; 38(2):226-235. PubMed ID: 31190487
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer.
Shiota M; Blas L; Kobayashi S; Matsumoto T; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
Int J Urol; 2022 Jan; 29(1):26-32. PubMed ID: 34549837
[TBL] [Abstract][Full Text] [Related]
9. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
10. Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer.
Hiroshige T; Eguchi Y; Yoshizumi O; Chikui K; Kumagai H; Kawaguchi Y; Onishi R; Hayashi T; Watanabe K; Mitani T; Saito K; Igawa T
Oncol Lett; 2018 May; 15(5):6806-6814. PubMed ID: 29725416
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
12. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel.
Li JR; Chiu KY; Wang SS; Yang CK; Chen CS; Ho HC; Hung CF; Cheng CL; Yang CR; Chen CC; Wang SC; Lin CY; Chang CH; Hsu CY; Ou YC
Front Pharmacol; 2017; 8():836. PubMed ID: 29213237
[No Abstract] [Full Text] [Related]
14. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
[TBL] [Abstract][Full Text] [Related]
15. External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer.
Nakano K; Komatsu K; Kubo T; Natsui S; Nukui A; Kurokawa S; Kobayashi M; Morita T
BMC Urol; 2014 Apr; 14():31. PubMed ID: 24742323
[TBL] [Abstract][Full Text] [Related]
16. Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer.
Matsuyama H; Shimabukuro T; Hara I; Kohjimoto Y; Suzuki K; Koike H; Uemura H; Hayashi T; Ueno M; Kodaira K; Tomita Y; Sakurai T; Shimizu N
Int J Clin Oncol; 2014 Oct; 19(5):946-54. PubMed ID: 24272390
[TBL] [Abstract][Full Text] [Related]
17. Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up.
Kobayashi T; Terada N; Kimura T; Matsubara N; Murakami K; Mori K; Fujimoto Y; Akamatsu S; Inoue T; Ogawa O
Clin Genitourin Cancer; 2020 Feb; 18(1):e46-e54. PubMed ID: 31759831
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience.
Nakano K; Ohta S; Komatsu K; Kubo T; Nukui A; Suzuki K; Kurokawa S; Kobayashi M; Morita T
BMC Urol; 2012 Feb; 12():3. PubMed ID: 22353627
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice.
Song G; Lee C; You D; Jeong IG; Hong JH; Ahn H; Kim CS
Prostate Int; 2013; 1(3):125-32. PubMed ID: 24223414
[TBL] [Abstract][Full Text] [Related]
20. Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade.
Nagai T; Naiki T; Iida K; Etani T; Ando R; Hamamoto S; Sugiyama Y; Akita H; Kubota H; Hashimoto Y; Kawai N; Yasui T
Prostate Int; 2018 Mar; 6(1):18-23. PubMed ID: 29556485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
